Standout Papers

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (... 2017 2026 2020 2023 988
  1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology
  2. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology

Citation Impact

3 by Nobel laureates 24 from Science/Nature 73 standout
Sub-graph 1 of 18

Citing Papers

Y chromosome loss in cancer drives growth by evasion of adaptive immunity
2023 StandoutNature
LAG-3 as the third checkpoint inhibitor
2023 Standout
1 intermediate paper

Works of Joel Jiang being referenced

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2018 Standout
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
2016

Author Peers

Author Oncology Molecular Biology PRM Immunology Last Decade Papers Cites
Joel Jiang 2379 944 640 908 23 3.5k
Sasun Yakubov 25 321
M. Dulick 32 1.0k
Gillian Wheater 79 115 5 26 7 345
Kannayakanahalli M. Dayananda 9 84 40 80 12 313
Manuel E. Ruiz-Sandoval 1 9 550

All Works

Loading papers...

Rankless by CCL
2026